Insignificant role of bacillus Calmette-Guérin maintenance therapy after complete transurethral resection of bladder tumor for intermediate- and high-risk non-muscle-invasive bladder cancer: Results from a randomized trial
- PMID: 27416975
- DOI: 10.1111/iju.13167
Insignificant role of bacillus Calmette-Guérin maintenance therapy after complete transurethral resection of bladder tumor for intermediate- and high-risk non-muscle-invasive bladder cancer: Results from a randomized trial
Abstract
Objectives: To investigate the effect of bacillus Calmette-Guérin maintenance therapy on patients with intermediate- and high-risk non-muscle-invasive bladder cancer receiving aggressive complete transurethral resection of bladder tumors standardized by well-trained surgeons.
Methods: A total of 95 patients were prospectively enrolled. Patients were diagnosed with multiple or recurrent non-muscle-invasive bladder cancer (Ta and T1), or with carcinoma in situ after complete transurethral resection of bladder tumors. Patients with Ta or T1 tumors without carcinoma in situ received six bacillus Calmette-Guérin instillations as induction therapy. Those with carcinoma in situ underwent eight bacillus Calmette-Guérin instillations as induction therapy. The patients were randomized into maintenance and non-maintenance groups. The maintenance group received intravesical bacillus Calmette-Guérin instillations once a week for 3 weeks at 3, 6, 12 and 18 months after bacillus Calmette-Guérin instillation. The primary end-point was recurrence-free survival.
Results: A total of 88 patients were evaluated. The average follow-up period was 48.3 ± 19.0 months. Five-year recurrence-free survival rates for the maintenance and non-maintenance groups were 80.1% and 79.3%, respectively. Five-year progression-free survival rates of the maintenance and non-maintenance groups were 92.4% and 85.3%, respectively. Recurrence- and progression-free survival rates did not significantly increase in the maintenance group compared with that in the non-maintenance group.
Conclusions: Bacillus Calmette-Guérin maintenance therapy did not improve recurrence- and progression-free survival rates after the initial complete transurethral resection of bladder tumors compared with that after bacillus Calmette-Guérin induction therapy alone.
Keywords: bacillus Calmette-Guérin; complete transurethral resection of bladder tumors; high-risk non-muscle-invasive bladder cancer; maintenance therapy; random control trial.
© 2016 The Japanese Urological Association.
Similar articles
-
Outcomes of bacillus Calmette-Guérin therapy without a maintenance schedule for high-risk non-muscle-invasive bladder cancer in the second transurethral resection era.Int J Urol. 2022 Mar;29(3):251-258. doi: 10.1111/iju.14761. Epub 2021 Dec 11. Int J Urol. 2022. PMID: 34894009 Free PMC article.
-
EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.Eur Urol. 2016 Jan;69(1):60-9. doi: 10.1016/j.eururo.2015.06.045. Epub 2015 Jul 23. Eur Urol. 2016. PMID: 26210894 Clinical Trial.
-
The role of tumor-free status in repeat resection before intravesical bacillus Calmette-Guerin for high grade Ta, T1 and CIS bladder cancer.J Urol. 2010 Jun;183(6):2161-4. doi: 10.1016/j.juro.2010.02.026. J Urol. 2010. PMID: 20399454
-
Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.J Urol. 2017 May;197(5):1189-1199. doi: 10.1016/j.juro.2016.12.090. Epub 2016 Dec 24. J Urol. 2017. PMID: 28027868
-
Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer.Cochrane Database Syst Rev. 2000;2000(4):CD001986. doi: 10.1002/14651858.CD001986. Cochrane Database Syst Rev. 2000. PMID: 11034738 Free PMC article.
Cited by
-
Dose, duration and strain of bacillus Calmette-Guerin in the treatment of nonmuscle invasive bladder cancer: Meta-analysis of randomized clinical trials.Medicine (Baltimore). 2017 Oct;96(42):e8300. doi: 10.1097/MD.0000000000008300. Medicine (Baltimore). 2017. PMID: 29049231 Free PMC article.
-
BCG therapy in bladder cancer and its tumor microenvironment interactions.Clin Microbiol Rev. 2025 Jun 12;38(2):e0021224. doi: 10.1128/cmr.00212-24. Epub 2025 Mar 20. Clin Microbiol Rev. 2025. PMID: 40111053 Review.
-
Intravesical Bacillus Calmette-Guerin (BCG) Therapy for Non-muscle Invasive Bladder Cancers: Long-term Results of a Modified Schedule.Indian J Surg Oncol. 2021 Dec;12(4):796-801. doi: 10.1007/s13193-021-01439-w. Epub 2021 Sep 9. Indian J Surg Oncol. 2021. PMID: 35110905 Free PMC article.
-
Effects of intravesical BCG maintenance therapy duration on recurrence rate in high-risk non-muscle invasive bladder cancer (NMIBC): Systematic review and network meta-analysis according to EAU COVID-19 recommendations.PLoS One. 2022 Sep 8;17(9):e0273733. doi: 10.1371/journal.pone.0273733. eCollection 2022. PLoS One. 2022. PMID: 36074771 Free PMC article.
-
Intravesical bacillus Calmette-Guerin (BCG) in treating non-muscle invasive bladder cancer-analysis of adverse effects and effectiveness of two strains of BCG (Danish 1331 and Moscow-I).Asian J Urol. 2022 Apr;9(2):157-164. doi: 10.1016/j.ajur.2021.05.002. Epub 2021 May 18. Asian J Urol. 2022. PMID: 35509489 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical